What dna Communications does

dna Communications is a healthcare-focused B2B public relations and scientific communications agency founded in 2007 and headquartered in New York. The firm serves pharmaceutical companies, biotechnology innovators, and healthcare brands, providing integrated services across five functional pillars: Scientific Communications, Strategy, Creative, Media Relations, and Integrated Media. Its core proposition is translating complex scientific and clinical information into narratives that drive understanding and behavior change among patients, healthcare professionals, and policymakers. The agency operates a global delivery footprint with eight offices across four regions — New York, Chicago, and Boston in the Americas; London, Cologne, and Frankfurt in EMEA; Hong Kong in APAC; and São Paulo in LATAM — enabling region-local execution for multinational clients.

The agency's most significant recent product initiative is dnaHelix, a dedicated global strategic communications support offering for biotech companies launched in November 2025. Beyond dnaHelix, revenue is generated through custom, negotiated professional services engagements with enterprise healthcare clients; pricing is not publicly disclosed and is consistent with quote-based, project-and-retainer structures typical of healthcare PR agencies. The firm's go-to-market is enterprise field sales targeting large pharma, biotech, and healthcare brand buyers. Internally, the senior leadership team includes Mike Rosich (CEO), Sara Baker (General Manager, Head of North America), Sandra Wagner (Senior Vice President and Head of Germany), and Candice Hardie (Vice President), supported by discipline leads across Scientific Communications, Strategy, Creative, Media Relations, and Integrated Media.

The business operates as a privately held agency with no disclosed parent company, institutional investors, or external funding. The ownership structure is not publicly disclosed, but the absence of funding data, M&A activity, or public listing references is consistent with an independent, bootstrapped professional services firm. The company has accumulated industry recognition including the 2025 MM+M Agency 100 designation, MM+M Agency of the Year (Silver), MM+M Gold Award, Clio Health Silver, PRovoke Media Sabre Award North America, PRNews Top 100 and Top 120 Agency Elite listings, and PRWeek Best Places to Work (midsize agency, 2024), positioning it as a credible mid-tier healthcare communications partner globally.

Name

dna Communications

Legal name

DNA Communications

Website

https://dna-comms.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

dna Communications is a privately held healthcare communications and public relations agency founded in 2007, serving pharmaceutical, biotechnology, and healthcare brand clients globally through eight offices across the Americas, EMEA, APAC, and LATAM.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Healthcare Communications Services: DNA Communications generates revenue through professional services engagements as a healthcare communications and PR agency, providing scientific communications, strategy, creative, media relations, and integrated media services to healthcare innovators and brands.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

dna Communications is a B2B healthcare communications and PR agency that provides scientific communications, strategy, creative, media relations, and integrated media services to pharmaceutical companies, biotech innovators, and healthcare brands. The agency operates specialized teams under a unified philosophy focused on translating complex scientific breakthroughs into meaningful health impact, and has launched dnaHelix as a dedicated global strategic communications support service for biotech companies.

Product overview

dna Communications is a healthcare communications and PR agency offering a unified service portfolio centered on scientific communications, strategy, creative, media relations, and integrated media. The agency recently launched dnaHelix as a dedicated global strategic communications support service for biotech companies. The core offering consists of specialized teams (Scientific Communications, Strategy, Creative, Media Relations, Integrated Media) working collaboratively under a unified philosophy focused on meaningful science and meaningful insights.

Differentiator

Problem solved

Functional benefit

Brands

• dnaHelix: Global strategic communications support for biotechs

Products and services

• dnaHelix

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• GCI Health: Healthcare-specialist public relations agency serving pharmaceutical, biotech, and consumer health clients with comparable scientific communications and patient-focused messaging offerings.
• Avalere Health (Fishawack): Healthcare consultancy with integrated communications offerings, serving biopharma clients globally with comparable scientific and brand communications expertise.
• Real Chemistry: Healthcare-focused communications and marketing agency serving pharma and biotech clients with a similar integrated scientific communications model.
• Chamberlain Healthcare PR (now within Evoke): Long-standing healthcare-focused PR firm now operating inside the Evoke network, historically serving biotech specialty pharma with similar scientific narrative positioning.
• Evoke (Ashfield Health): Specialized healthcare communications and public relations agency operating within a global health-adjacent network, directly competitive with DNA Communications on biotech and pharma accounts.

Broad incumbents

• Edelman (Health): World's largest PR firm with a substantial healthcare and biotech practice serving global pharmaceutical clients, frequently competing against midsize specialists on enterprise pitches.
• Syneos Health Communications: Large CRO/communications platform with healthcare public relations and medical communications capabilities, offering broader clinical-commercial integration than DNA Communications.
• Ketchum (Health): Global PR agency with a health practice providing scientific storytelling, media relations, and integrated campaigns to pharmaceutical, biotech, and health-system clients.
• Weber Shandwick (Healthcare Practice): Global PR network with a dedicated healthcare practice serving pharma, biotech, and consumer health clients; competes for large enterprise healthcare communications mandates.
• FleishmanHillard (Healthcare): Global communications agency with a deep healthcare and life-sciences practice offering media relations, scientific communications, and integrated marketing to pharma clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dnacommunications
• Instagraminstagram.com/dna.communications/?hl=en
• Facebookfacebook.com/dnaComms

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about dna Communications